Loading...

FGEN FIBROGEN INC Company Mergers 8-K Filing

FBRG

FGN

FIBROGEN INC

(FGEN)

2025 8-K

Show Summary

Summary

Asset Sale Completed

Acquisition Announcement

Financing Agreement Update

Debt-Equity Swaps

Divestment of Assets

Reverse Stock Split

Financial Statements

Bylaw Amendment

Drug Publication

Agreement Amendments

Financial Update

Equity Offering

Management Change

Q3 Financial Results

Lease Termination

Director Resignations

Executive Departures

Restructuring Plan

Financial Results and Busin...

Investor Presentation

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Delisting Notice

Appointment of CEO and Dire...

Resignation of Chief Medica...

Financial Results Announcement

Appointments, resignations

Management changes

Annual Meeting of Stockholders

Positive Results from Phase...

Financial Results Announcement

Financing Agreement

External Links:

On August 29, 2025, FibroGen Inc. sold FibroGen International (Hong Kong) Ltd. to AstraZeneca for about $220 million, including $85 million in enterprise value and $135 million in net cash. FibroGen will retain rights to its product roxadustat in certain regions.

AI Assistant

FIBROGEN INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.